Research on E-cigarette in Chile: Risks, Standards, and Regulations

Industry Insight by 2FIRSTS.ai
Dec.01.2023
Research on E-cigarette in Chile: Risks, Standards, and Regulations
Chile's consumer protection agency, Sernac, has released a study analyzing the risks and quality standards of e-cigarettes.

The Chilean National Consumer Service (Sernac) has released a study on e-cigarettes on November 30th. The study analyzes the risks and quality standards of these products, as well as their regulatory framework within the country. Sernac has received nearly 170 complaints regarding e-cigarette vaporizer products in recent years.

 

Sernac has conducted a total of 558 reviews of e-cigarettes or vaporizers sold online, which were offered by 16 companies and correspond to 56 brands. The offline investigation involved 16 companies, corresponding to 14 brands and 80 different models.

 

All the products analyzed lack proper sanitary registration, including those that openly claim to be nicotine-free. Additionally, the analyzed brands have failed to adhere to the requirement of providing "health warnings" in their reports, with only 21% of brands obliging to "recommend keeping the products out of the reach of children.

 

From January 2018 to January 2023, a total of 171 cases related to e-cigarette products were recorded by Sernac.

 

The companies with the highest number of complaints are Vaporizadores Chile (11.7%), Santivape (8.8%), Quema Smokeshop (8.2%), Zigzaboo (7.6%), Tigo Vape (6.4%), Freesmoke (5.8%), chileVapea (2.9%), and Vapea Chile (2.3%).

 

In consumer complaints, contract issues top the list, accounting for 62% of the total. Examples include delayed delivery of purchased products, which accounts for 17% of the complaints.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
From Tamarind’s AI Shift to Industry Restructuring, The ‘Amazon Moment’ for Nicotine Is Approaching
Tamarind Intelligence’s decision to appoint a technology-sector executive as chief executive officer signals more than a leadership reshuffle at a specialist data firm. It reflects a broader structural shift across the global nicotine industry, where companies, regulators and intelligence providers are embedding artificial intelligence into core operations.
Special Report
Feb.18
MEPs seek Commission answers over EU trade officials’ contacts with PMI
MEPs seek Commission answers over EU trade officials’ contacts with PMI
POLITICO reports that five members of the European Parliament’s health committee want to invite the European Commission to answer questions about its contacts with Philip Morris International (PMI), following a POLITICO and The Examination investigation into extensive meetings between EU trade officials and tobacco lobbyists.
Jan.15 by 2FIRSTS.ai
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Report: 43% of 546 Canadian specialty vape shops found non-compliant in federal inspections
Health Canada’s vaping compliance and enforcement report covering inspections from April 2024 to March 2025 found 43% of 546 specialty vaping businesses were not compliant with the Tobacco and Vaping Products Act and the Canada Consumer Product Safety Act, according to the report cited. Health inspectors seized vaping products at 235 specialty vaping establishments.
Feb.26 by 2FIRSTS.ai
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
India has reaffirmed its 2019 ban on e-cigarettes and heated tobacco devices, effectively blocking Philip Morris International (PMI) from launching IQOS in the country despite years of lobbying. Together with Taiwan, China’s conditional opening of heated tobacco products, and Japan’s planned 2026 excise tax hikes, these moves highlight increasingly divergent national regulatory pathways—an external uncertainty shaping PMI’s smoke-free growth trajectory.
Feb.12
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
Louisiana lawmaker pushes bill to ban vape product sales within 300 feet of schools
A Louisiana lawmaker has introduced HB 302, which would prohibit businesses from selling vapor products within 300 feet of schools. The bill would measure the distance by a person walking on the sidewalk from the nearest point on school property to the nearest point of the business. It would also give the commissioner authority to modify how the distance is calculated, while maintaining the 300-foot limit.
Feb.26 by 2FIRSTS.ai